Drug Profile


Alternative Names: INCSHR1210; SHR1210

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Incyte Corporation; Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hepatocellular carcinoma
  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Breast cancer; Malignant melanoma

Most Recent Events

  • 20 Mar 2017 Jiangsu HengRui Medicine plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in China (NCT03083041)
  • 01 Jan 2017 Phase-II clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in China (Parenteral) (NCT03085069)
  • 07 Nov 2016 Incyte completes enrolment in its phase I trial for Solid tumours (Late-stage disease, Second line therapy or greater) in Australia (NCT02492789)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top